Alnylam Pharmaceuticals
ALNY
#509
Rank
โ‚น4.286 T
Marketcap
โ‚น32,447
Share price
-2.07%
Change (1 day)
49.56%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): โ‚น15.44

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is โ‚น8.13. In 2023 the company made an earnings per share (EPS) of -โ‚น318.81 an increase over its 2022 EPS that were of -โ‚น839.03.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)โ‚น15.44
2023-โ‚น318.81-62%
2022-โ‚น839.0329.03%
2021-โ‚น650.27-3.36%
2020-โ‚น672.85-8.48%
2019-โ‚น735.167.67%
2018-โ‚น682.7839.74%
2017-โ‚น488.6012.94%
2016-โ‚น432.6138.84%
2015-โ‚น311.59-32.88%
2014-โ‚น464.22259.44%
2013-โ‚น129.15-31.25%
2012-โ‚น187.86

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-โ‚น112.89-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น3,923 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น247.46-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น21.68-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น65.93-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น664.72 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น334.68 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น56.90 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel